Skip to main content
. 2020 Jul 22;9(5):596–612. doi: 10.1159/000508809

Fig. 1.

Fig. 1

Subdivision of high-burden intermediate-stage HCC patients receiving TACE into two common clinical courses. Group A: patients with high tumor burden at the time of diagnosis of intermediate-stage disease. Group B: patients with low tumor burden at the time of diagnosis of intermediate-stage disease and progression to high tumor burden during the clinical course. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization.